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DOI 10.1016/j.ccr.2010.11.014SUMMARYWe investigated the engraftment properties and impact on patient outcome of 50 pediatric acute lympho-
blastic leukemia (ALL) samples transplanted into NOD/SCID mice. Time to leukemia (TTL) was determined
for each patient sample engrafted as weeks from transplant to overt leukemia. Short TTL was strongly
associated with high risk for early relapse, identifying an independent prognostic factor. This high-risk
phenotype is reflected by a gene signature that upon validation in an independent patient cohort (n = 197)
identified a high-risk cluster of patients with early relapse. Furthermore, the signature points to independent
pathways, including mTOR, involved in cell growth and apoptosis. The pathways identified can directly be
targeted, thereby offering additional treatment approaches for these high-risk patients.INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most frequent malig-
nant disease in children and adolescents. Although intensifica-
tion of multiagent chemotherapy regimens and advances in
supportive care have led to improvement of remission induction
and long-term survival over the last decades presently achieving
cure rates of over 80%, about 20% of the patients suffer from
relapse associated with an inferior prognosis (Pui and Evans,
2006; Schrappe et al., 2000a, 2000b). Particularly, in 10% of all
patients, relapse occurs at early time points associated with
a substantially reduced survival of 5% or less (Gaynon et al.,Significance
Treatment of pediatric ALL is increasingly successful, achievi
outcome; however, the majority of relapsed patients is initially
markers. This emphasizes the need for additional factors for
describe a strong association of the engraftment phenotype f
in a mouse in vivo model and patients with early relapse. Ge
with this aggressive phenotype providing a potential strategy
ways regulating cell growth are identified, providing targets fo
206 Cancer Cell 19, 206–217, February 15, 2011 ª2011 Elsevier Inc.1998; Henze et al., 1991; Lawson et al., 2000). Stratification of
patients into therapy regimens of different intensity is based on
the individual risk for relapse by using prognostic factors
including cytogenetics and response to therapy to define
different risk groups (high-risk, HR and non-high risk, non-HR)
(Pui et al., 2004a; Schrappe et al., 2000b; Silverman and Sallan,
2003). Leukemia cell clearance in response to steroid treatment
is evaluated and has been used as a prognostic marker for
almost 20 years, demonstrating inferior survival for patients
responding poorly to prednisone (Gajjar et al., 1995; Riehm
et al., 1987; Schrappe et al., 1998, 2000a, 2000b). In addition,
detection of residual leukemia cells at submicroscopic levelsng cure rates of over 80%. Relapse is associated with poor
stratified into low-risk groups based on current stratification
upfront identification of high-risk patients. In this study we
ound in a series of transplanted primary pediatric ALL cells
ne expression profiling revealed a set of genes associated
to identify these high-risk patients. Most importantly, path-
r alternative therapeutic strategies.
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Figure 1. Distinct Engraftment Properties of NOD/SCID/huALL
(A) In vivo expansion of leukemia cells in different organ compartments of
recipients over time. Two NOD/SCID/huALL samples (TTLshort, light gray;
TTLlong, dark gray) were transplanted into recipient mice (n = 3 per group),
and the proportions of huCD19 positive ALL cells were detected in bone
marrow (rhombs, dotted lines), spleen (squares, dashed lines), or peripheral
blood (triangles, solid lines) by flow cytometry. Data are given as mean of
triplicates with standard deviation.
(B) TTL of engrafted transplants (n = 29). Each data point represents the mean
TTL in weeks for every individual leukemia transplanted (n = 2 recipients).
Some samples lead to disease within a short period of time (TTLshort, n = 6,
mean 6.8 weeks) in contrast to samples showing leukemia manifestation after
a longer time period (TTLlong, n = 23, mean 19.0 weeks; t test p = 2.8 e-8).
(C) NOD/SCID/huALL samples (n = 4) with either a TTLlong (25 or 18 weeks) or
TTLshort (9 weeks) phenotype were retransplanted onto subsequent recipients
injecting 13 105, 13 106, 13 107, or 33 107 cells per animal (n = 2 per group),
and TTL was assessed for each recipient.
See also Figure S1 and Tables S1–S4.
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MRD) qualifies for HR treatment (Chessells et al., 1995; Conter
et al., 2010; Flohr et al., 2008; Steinherz et al., 1996; van Dongen
et al., 1998). Early identification of patients with high risk for
relapse has led to improved outcome. However, two-thirds of
patients encountering relapse were initially stratified into non-
HR groups (Schrappe et al., 2000a). This limitation of prognostic
factors emphasizes the need to identify novel parameters that
ideally also reflect the functional biology of the disease for the
development of molecular-based risk stratification and identifi-
cation of therapeutic targets.
Although leukemia cells cannot sufficiently be cultured in vitro,
xenograft models can overcome these limitations. Transplanta-
tion of primary leukemia cells into NOD/SCID mice results in
recipients exhibiting leukemia recapitulating the human disease
(Baersch et al., 1997; Borgmann et al., 2000; Lock et al., 2002;
Nijmeijer et al., 2001). We adopted the NOD/SCID/huALL model
and observed that rapid development of leukemia in NOD/SCID
mice engrafted with primary ALL cells is characteristic for
patients with early relapse.
RESULTS
NOD/SCID/huALL
Leukemia cells isolated from diagnostic samples of 50 patients
with pediatric de novo B cell precursor (BCP) ALL were trans-
planted onto NOD/SCIDmice (13 107 cells per recipient). Recip-
ient mice were investigated regularly for the presence of
leukemia and sacrificed at manifestation of disease. Leukemia
was confirmed by detection of a high percentage of human
leukemia cells in the peripheral blood of the mice and infiltration
of bone marrow and spleen by leukemia cells using flow cytom-
etry. Of 50 samples, 29 led to manifestation of overt leukemia
during the observation time of 20 weeks, whereas 21 transplants
did not manifest disease within this time. Engraftment of
leukemia was also monitored in different organ compartments
at different time points. As exemplified for two samples,
leukemia was consistently first detected in bone marrow and
spleen followed by the occurrence of ALL cells in peripheral
blood (Figure 1A).
Time to Leukemia
When we analyzed leukemia engraftment of different samples,
we observed a prominent difference in time elapsing from
transplantation to manifestation of leukemia. Rapid onset of
leukemia-related morbidity was observed in some samples
(4–6, 8, and 9 weeks after transplant) in contrast to other
samples, giving rise to leukemia after a substantially longer
period of time (12–26 weeks). No onset of leukemia was
observed between 9 and 12 weeks after transplant, suggesting
distinct engraftment phenotypes of different leukemia cell
samples. The time from transplant to leukemia was defined as
‘‘Time To Leukemia’’ (TTL) and quantified for each leukemia
sample. A threshold of 10 weeks was used to distinguish the
rapid from the slow engraftment phenotype: a TTL of less than
10 weeks was designated TTLshort, and longer time periods
were classified as TTLlong (Figure 1B).
Additional cutoff points representing intervals at 16 and
21 weeks (see Figure S1 available online) and leukemia charac-Cteristics (ALL-BFM high-risk stratification, TEL/AML1 fusion,
prednisone-poor response (PPR), age, and white blood cells at
diagnosis) were tested to divide the cohort. Age (unfavorable:
0–1 and older than 9 years; favorable: 1–9 years) and hyperleu-
kocytosis at diagnosis (above or below 50 white blood cells
[1000/ml]) were classified according to St. Jude’s Total Therapy
Study XIIIB protocol criteria (Pui et al., 2004b). Time to overt
leukemia (in the recipient mice) and relapse-free survival (of theancer Cell 19, 206–217, February 15, 2011 ª2011 Elsevier Inc. 207
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NOD/SCID/huALL Engraftment Identifies ALL Relapsepatients) were compared between the subgroups divided
according to the different cutoff points and pretreatment and
clinical response features by Kaplan-Meier analysis and log
rank test. Resulting p values were adjusted for multiplicity (Bon-
ferroni’s method) with the most distinct grouping according to
the lowest adjusted significant p value. The 10-week cutoff point
was shown to be most discriminatory with respect to engraft-
ment and relapse-free survival (Tables S1 and S2).
Of the 50 samples transplanted, 21 samples did not expand
in vivo to substantial cell numbers within the observation time.
Leukemia manifestation after week 20 was not analyzed system-
atically in our study. However, two leukemias were followed
up for a prolonged time and showed disease manifestation
with a TTL of 36 and 44 weeks, suggesting that eventually all of
the transplanted leukemia cell samples lead to overt leukemia
if the observation time is long enough. The samples showing
no overt leukemia at week 20 were included into the TTLlong
group.
Stability, Consistency, and Independency
of the TTL Phenotype
TTL was in all cases assessed after transplantation of 1 3 107
of primary patient leukemia cells. Sets of primary leukemia
samples obtained at diagnosis were transplanted in parallel
(1 3 107 cells), and TTL was assessed for both recipients of
each leukemia sample. Similar TTL values were observed within
the replicates of 21 primary leukemia samples (Table S3).
Furthermore, two leukemia samples obtained at relapse were
transplanted as replicates and compared to the respective
matching diagnosis samples. Similar TTL values were also
observed for the replicates of the relapse samples. Moreover,
similar TTL was seen comparing diagnosis-relapse pairs
(Table S3), indicating stability of the TTL phenotype, even at
leukemia relapse.
We also analyzed the consistency of TTL in subsequent recip-
ients. Leukemia cells of diagnostic patient samples and the
consecutive xenograft passages were transplanted in parallel
onto secondary and tertiary recipients using the identical dose
of 1 3 107 cells for each recipient. TTL was assessed for both
recipients of each passage, and similar TTL values were
observed constantly within the replicates. Thus, TTL phenotypes
did not change and remained TTLshort or TTLlong between diag-
nosis and consecutive passages in the NOD/SCID/huALL model
(Table S3).
Also, later passages were investigated. Representative xeno-
graft samples for TTLlong and TTLshort, as characterized upon
initial transplantation of the diagnostic sample, were retrans-
planted onto primary, tertiary, or sixth recipients. The dose of
1 3 107 cells per recipient, as used throughout the study, reca-
pitulated the TTL phenotype of the respective leukemia remain-
ing stable also after up to five passages (Figure 1C; Table S4).
We also addressed whether the TTL phenotype might be
influenced by varying numbers of cells transplanted. Higher
numbers of TTLlong leukemia cells (3 3 107 cells per animal)
did not accelerate engraftment, nor did a decrease of cell
numbers (1 3 106, 1 3 105 cells per mouse) prolong TTLshort,
demonstrating that the TTL phenotypes are largely independent
from cell numbers transplanted and represent an intrinsic feature
of the individual leukemia (Figure 1C; Table S4).208 Cancer Cell 19, 206–217, February 15, 2011 ª2011 Elsevier Inc.TTL and Patient Outcome
Six patients exhibited TTLshort and 44 TTLlong. Five of these six
patients with TTLshort encountered medullar relapse within
24 months after diagnosis. This corresponds to the expected
proportion of about 10% of patients at very high risk/with early
relapse.
We analyzed relapse-free survival of the patients whose
leukemia cells were used for transplant. Patients whose trans-
planted cells showed a TTLlong phenotype revealed a marked
superior relapse-free survival compared to TTLshort patients.
Most interestingly, all relapses of the patients characterized by
TTLshort occurred early within the first 2 years after diagnosis
(Figure 2A). Thus, the TTLshort phenotype is characteristic for
patients at high risk for early relapse.
Because the majority of relapse patients originates from the
low-risk groups, we analyzed whether TTL identifies patients
who would encounter an early relapse despite stratification
into low-risk groups. Therefore, the analysis was focused on
the non-high risk group patients (n = 43: TTLshort n = 4, TTLlong
n = 39). A clear inferior relapse-free survival of TTLshort patients
was observed; all four non-HR patients characterized by TTLshort
developed early medullar relapse within 24 months after diag-
nosis (Figure 2B). This demonstrates that TTL is associated
with patient outcome independent of risk stratification.
Twenty-one leukemia samples did not lead to leukemia in the
recipients within the observation time and were, therefore,
included into the TTLlong group. We also analyzed whether this
non-engraftment subgroup would be associated with a distinct
patient outcome. Most importantly, the group of patients whose
leukemia cells upon transplant did not lead to leukemia within
20 weeks of observation exhibited further increased superior
relapse-free survival, even achieving 100% survival in the non-
HR group (Figures 2C and 2D).
A superior relapse-free survival was also observed if only
patient samples leading to overt leukemia (all risk groups,
n = 29; non-high risk groups, n = 25) were analyzed, and patients
whose leukemia cells did not engraft were excluded (Figures 2E
and 2F). Furthermore, a significant correlation of TTL (mouse
model) and remission duration (patients) was observed analyzing
engrafted samples of relapsed patients (n = 9, all risk groups;
n = 7, non-HR groups) (Figures 2G and 2H).
In summary the TTL phenotype is highly associated to patient
survival, i.e., TTLshort identifies patients with early relapse, and
TTLlong is characteristic for superior relapse-free survival of up
to 100%, regardless of stratification into risk groups.
Prognostic Impact of TTL
Different prognostic factors have been implemented in different
treatment protocols to stratify patients based on their individual
risk. We compared the prognostic impact of TTL to established
prognostic factors: poor leukemia cell clearance in response to
steroid treatment (PPR); hyperleukocytosis (highly elevated
white blood cell counts >50 [1000/ml] in the peripheral blood at
diagnosis); and unfavorable age (age at diagnosis younger
than 1 and older than 9 years) were included (Pui et al., 2004b).
By multivariate Cox’s regression, patients with TTLshort exhibited
a 45-fold increased risk for relapse in contrast to no significant
elevated risk for patients with PPR, high white blood cell count
at diagnosis, or unfavorable age in this cohort (Table 1).
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Figure 2. Superior Relapse-Free Survival
of Patients with TTLlong
Relapse-free survival (RFS) of patients with TTLlong
or TTLshort phenotypes (for A–F, P values by log
rank test).
(A) All RG (n = 50: TTLlong n = 44; TTLshort n = 6;
p = 2.9 e-10).
(B) Non-HR stratified patients only (n = 43: TTLlong
n = 39, TTLshort n = 4; p = 3.0 e-13).
(C) RFS of patients with TTLlong, TTLshort, or with no
leukemia manifestation within 20 weeks after
transplant; all RG (n = 50: non-engrafted n = 21;
TTLlong n = 23; TTLshort n = 6; p = 1.5 e-9).
(D) Non-HR (n = 43: non-engrafted n = 18; TTLlong
n = 21; TTLshort n = 4; p = 1.5 e-12).
(E) Analysis of the group of patients whose
samples engrafted, all RG (n = 29: TTLlong,
n = 23; TTLshort, n = 6; p = 1.8 e-6).
(F) Non-HR (n = 25: TTLlong, n = 21; TTLshort, n = 4;
p = 7.9 e-8).
(G) Spearman correlation of TTL (mouse) to time
from diagnosis to relapse (remission duration) of
relapsed patients; all RG (n = 9, rho = 0.731,
p = 0.03).
(H) Non-HR (n = 7, rho = 0.782, p = 0.04).
See also Figure S2..
Cancer Cell
NOD/SCID/huALL Engraftment Identifies ALL RelapseAlso, in comparison to additional thresholds to determine TTL
(16 and 21 weeks), TTLshort defined by the 10-week cutoff was
the most significant prognostic factor (Table S5).
Genetic alterations are common in pediatric ALL and might be
associated with favorable or unfavorable outcome and are,
therefore, used for treatment stratification. The presence of
BCR/ABL or MLL/AF4 fusion genes qualifies for HR stratification
(Flohr et al., 2008; Schrappe et al., 2000a). In the group studied,
one patient was positive for MLL/AF4 and displayed a TTLshort
phenotype. No patients positive for BCR/ABL were included.
TEL/AML1 fusion is associated with favorable outcome
(Pui et al., 2004a). Most interestingly, all 19 patients positive for
TEL/AML1 showed TTLlong. In addition, only one of the 50
patients included in this study met criteria for MRD-based
high-risk stratification. However, this patient was high-risk strat-
ified due to PPR and showed TTLlong. Pretreatment characteris-
tics and response features such as age, gender, peripheralCancer Cell 19, 206–217,leukocyte count at diagnosis, and
achievement of remission at the end of
induction therapy (day 33) are not associ-
ated with TTLlong or TTLshort (Table 2).
TTL Is Confirmed in an Independent
Leukemia Subset
To evaluate the significance of the TTL
phenotype, an independent subset of
cell bank BCP-ALL samples (four pairs
matched for age, gender, and low-risk
group classification either showing early
relapse or not) was transplanted. Patients
with early relapse always revealed
a shorter TTL than patients with late or
no relapse. However, transplant of onefrozen cell bank sample derived from a patient with early relapse
showed a ‘‘borderline’’ TTL of 13 weeks (Figure S2A). TTL was
significantly associated with the time from diagnosis to relapse
(remission duration) (Figure S2B), confirming the prognostic
value of TTL.
Gene Expression Analysis of Xenograft Leukemia
To gain insight into molecular mechanisms responsible for
distinct in vivo leukemia proliferation, gene expression profiles
were analyzed using a human whole-genome array approach.
ALL cells isolated from leukemia-bearing recipients (TTLlong or
TTLshort) were investigated. Cytogenetic abnormalities leading
to fusion genes and involving transcription factors are recog-
nized by specific transcription profiles (Yeoh et al., 2002) and
might overcast other differences in gene regulation. Therefore,
the analysis has been focused on xenografts derived from
patients without known gene fusions and also sufficientFebruary 15, 2011 ª2011 Elsevier Inc. 209
Table 1. Prognostic Relevance of TTL
No. = 50 n p
Risk Ratio
(relapse) CI
TTLshort 6 6.25 e-5 45.08 6.98–290.94
PPR 6 0.05 5.61 0.99–31.70
Unfavorable age 18 0.11 3.34 0.76–14.73
Hyperleukocytosis 16 0.51 1.68 0.36–7.86
Multivariate analysis on relapse-free survival (Cox regression, n = 50)
including different risk factors: TTLshort phenotype; PPR; hyperleukocyto-
sis (leukocyte count at diagnosis higher than 50 [1000/ml]); and unfavor-
able age (0–1 and >9 years); CI, confidence interval. See also Table S5.
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NOD/SCID/huALL Engraftment Identifies ALL Relapsefollow-up time (n = 12: TTLshort n = 5, TTLlong n = 7) (Table S6).
The expression profiles were analyzed employing a model-free
shrinkage estimate of the variance across genes ranking the
data set (‘‘shrinkage t’’ statistic; Opgen-Rhein and Strimmer
[2007]). Seventy-three genes (88 probe sets) were identified to
be differentially regulated between TTLshort and TTLlong (FDR <
5%): 51 genes upregulated and 22 downregulated in TTLshort
(Figure 3A and Table 3). Among the probe sets with the highest
fold changes, two genes involved in regulation of mammalian
target of rapamycin (mTOR) signaling were identified: DDIT4LTable 2. Patient Characteristics of De Novo BCP-ALL Samples
Transplanted
Total TTLlong TTLshort
No. % No. % No. %
Total 50 100 44 100 6 100
Gender Female 26 52 23 52 3 50
Male 24 48 21 48 3 50
Age 1–9 years 32 64 29 66 3 50
0–1 and
>9 years
18 36 15 34 3 50
Immunophenotype pro-B ALL 1 2 0 – 1 17
c-ALL 36 72 33 75 3 50
pre-B ALL 13 26 11 25 2 33
Fusion gene TEL/AML1 19 38 19 44 0 –
BCR/ABL 0 – 0 – 0 –
MLL/AF4 1 2 0 – 1 17
MLL/ENL 2 4 1 2 1 17
No 26 52 22 50 4 66
Not done 2 4 2 4 0 –
Hyperleukocytosis <50 (1000/ml) 16 32 12 27 4 67
>50 (1000/ml) 34 68 32 73 2 33
Prednisone
response (PR)
Good 44 88 39 89 5 83
Poor 6 12 5 11 1 17
MRD MRD-HR 1 2 1 2 0 –
MRD-non-HR 41 82 36 82 5 83
No MRD
available
8 16 7 16 1 17
Remission at day 33 Yes 50 100 44 100 6 100
Final risk groups Non-HR 43 86 39 89 4 67
HR 7 14 5 11 2 33
210 Cancer Cell 19, 206–217, February 15, 2011 ª2011 Elsevier Inc.and RHEB. DDIT4L codes for DNA-damage-inducible-tran-
script-4-like, amolecule negatively regulating mTOR. Consistent
with this function (i.e., inhibiting mTOR, a central molecule regu-
lating cell proliferation and survival), DDIT4L is upregulated in
TTLlong (inhibition of mTOR) and downregulated in TTLshort
(lack of mTOR inhibition). RHEB, coding for the positive mTOR
regulator Ras homolog enriched in brain, was identified to be up-
regulated in TTLshort leukemia by two probe sets. In line with its
mTOR-activating function, RHEB was found to be upregulated
in TTLshort/early-relapse leukemia.
In addition, two genes coding for molecules involved in regu-
lation apoptosis were identified displaying high fold changes:
PDE4A and DAPK1 (Table 3). The type 4 cyclic AMP phosphodi-
esterase PDE4A downregulates cAMP levels leading to impaired
apoptosis sensitivity. In line, PDE4A is upregulated in TTLshort/
early-relapse leukemia. DAPK1 codes for the proapoptotic
death-associated protein kinase and is congruent with its
apoptosis-sensitizing effect, highly expressed in TTLlong/good
prognosis leukemia.
Differential Regulation of Identified Genes
in Xenograft ALL
The differential regulation of transcripts identified in gene array
analysis was analyzed by quantitative RT-PCR. ALL xenograft
samples (n = 24: n = 12 used for array analysis and n = 12 without
analyzed gene profile; no known gene fusions, n = 9 TTLshort,
n = 15 TTLlong) were investigated. A significant differential regu-
lation of PDE4A, DDIT4L, and RHEB in TTLshort versus TTLlong
leukemia was confirmed (Figures 3B–3D). Additionally, also
FRAP1 coding for mTOR was analyzed and itself found to be
significantly upregulated in TTLshort (Figure 3E). Moreover, tran-
script levels of the mTOR regulators DDIT4L, RHEB, and
FRAP1 itself were also highly associated with TTL (Table S7).
Application of the Xenograft Signature
on an Independent Patient Cohort
To corroborate the relevance of the specific expression profile
identified in xenograft leukemia samples, the TTL signature was
applied onto profiles of an independent cohort of pediatric
patients with BCP-ALL (n = 197, samples isolated at diagnosis;
Table S8) that has also been treated according to a BFM-based
protocol (AIEOP-LLA-2000). This independent set of patient
profiles was analyzed with respect to the best distinction into
subgroups according to the signature by a cluster number
estimation procedure for k-means via repeated clusterings on re-
sampled versions of the data including a correction for random
partitions (Kraus and Kestler, 2010). Based on the 88 probe
sets, two robust clusters were identified within the 197 patients
(Figure S3A).
Most importantly, patients grouped into the TTLshort cluster
displayed a significantly inferior relapse-free survival in contrast
to patients clustering with the TTLlong profile (log rank test,
p = 2.5 e-4) (Figure 3F).
A Classifier Based on the TTL Signature Identifies
Patients with Early Relapse
The TTLshort phenotype and corresponding expression signature
are strongly associated with early-relapse leukemia. For this
reason we also analyzed whether, based on the TTL profile,
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Figure 3. The TTLshort Signature Is Associated with Poor Outcome
(A) Signature of 88 differentially regulated probe sets (73 genes; ‘‘shrinkage t’’ statistic, FDR < 5%) in xenograft leukemia. Unsupervised cluster analysis of xeno-
graft samples according to the TTL signature showing two clusters of TTLlong and TTLshort xenograft leukemia samples.
(B–E) Differential expression of individual genes in xenograft ALL samples (qRT-PCR; n = 24: TTLshort n = 9, TTLlong n = 15; Wilcoxon rank sum test); (B) PDE4A:
p = 0.018; (C) DDIT4L: p = 0.003; (D) RHEB: p = 0.003.; and (E) FRAP1: p = 0.001.
(F) Significant inferior relapse-free survival of patients of an independent BCP-ALL patient cohort (n = 197) who cluster with the TTLshort profile. Clustering into two
groups according to the TTL signature as determined by cluster number estimation analysis (see also Figure S3 and Tables S6–S8).
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relapse. A classifier was generated by conjunction of threshold
decisions on different genes using a set-covering machine
(SCM) with data-dependent rays (Kestler et al., 2006; Marchand
andShawe-Taylor, 2002). Starting from thewhole signature of 88
probes sets, the SCM reduced the number of genes employed in
the decision to a set showing best early-relapse prediction.
Utilizing 20probe sets (includingRHEB andDAPK1) (Figure S3B),
all patients with early relapse were identified. The set was refined
to further improve the robustness, yielding a subset of five probe
sets (Figure S3C). Applying this rule to the 197 patients, all 26
early-relapse cases are detected (100% sensitivity), with an
overall classification accuracy of 75%. Cross-validating (leave-
one-out) this classifier achieved a sensitivity of 77% and an
accuracy of 72%.CCell Death Is Predominantly Induced in TTLshort but Not
TTLlong Leukemia Cells
An activated (DDIT4Llow/RHEBhigh/FRAP1high) mTOR pathway
was found to be characteristic for the TTLshort phenotype.
Additionally, PDE4Ahigh was also associated with TTLshort
leukemia. Therefore, inhibition of mTOR or PDE4A might
successfully target TTLshort/early-relapse leukemia (Figures 4A
and 5A). Xenograft ALL samples (TTLshort or TTLlong) isolated
from recipient mice with overt leukemia were treated with either
the mTOR inhibitor rapamycin or the phosphodiesterase
inhibitor rolipram, and cell death was analyzed. Cell death was
found to be increased upon ex vivo rapamycin treatment in
most TTLshort (activated mTOR pathway) ALL cells, but not in
TTLlong leukemia samples (Figure 4B). Treatment with rolipram
also showed a stronger effect on the TTLshort (PDE4Ahigh)ancer Cell 19, 206–217, February 15, 2011 ª2011 Elsevier Inc. 211
Table 3. Gene Signature Associated with the TTL Phenotype
Upregulated in TTLshort Downregulated in TTLshort
Probe Set
Gene
Symbol FC Probe Set
Gene
Symbol FC
204735_at PDE4A 3.480 227798_at SMAD1 5.526
226736_at CHURC1 2.072 210993_s_at SMAD1 5.441
229814_at NA 1.821 203139_at DAPK1 4.497
236443_at NA 1.638 228057_at DDIT4L 3.809
222556_at ALG5 1.345 217800_s_at NDFIP1 3.409
226643_s_at NUDCD2 1.301 202973_x_at FAM13A 2.754
213409_s_at RHEB 1.247 227376_at GLI3 2.427
206508_at CD70 1.194 217047_s_at FAM13A 2.216
208844_at VDAC3 1.188 206142_at ZNF135 1.798
244110_at MLL 1.110 1559005_s_at CNTLN 1.781
223479_s_at CHCHD5 1.070 212158_at SDC2 1.605
221995_s_at MRP63 1.050 200998_s_at CKAP4 1.361
214395_x_at EEF1D 1.046 213955_at MYOZ3 1.313
229525_at THOC7 1.023 224151_s_at AK3 1.208
217426_at NA 1.017 200644_at MARCKSL1 1.128
233924_s_at EXOC6 1.009 201016_at EIF1AX 1.062
227364_at NA 0.995 205191_at RP2 1.039
1553690_at SGOL1 0.993 201019_s_at EIF1AP1 1.038
223210_at CHURC1 0.975 201017_at EIF1AX 0.986
235878_at TAF1B 0.878 219351_at TRAPPC2 0.938
204084_s_at CLN5 0.854 216929_x_at ABO 0.804
227352_at C19orf39 0.851 208655_at NA 0.786
216554_s_at NA 0.846 214678_x_at ZFX 0.783
226259_at EXOC6 0.843 221002_s_at TSPAN14 0.753
209276_s_at GLRX 0.824 213864_s_at NAP1L1 0.681
203270_at DTYMK 0.823 1564129_a_at NA 0.650
203554_x_at PTTG1 0.821 1556102_x_at LOC389906 0.598
233380_s_at RUFY1 0.821 – – –
235063_at C20orf196 0.819 – – –
218064_s_at AKAP8L 0.795 – – –
221598_s_at MED27 0.785 – – –
219324_at NOL12 0.777 – – –
223481_s_at MRPL47 0.759 – – –
218556_at ORMDL2 0.756 – – –
225901_at PTPMT1 0.746 – – –
226070_at C9orf142 0.726 – – –
204839_at POP5 0.723 – – –
205345_at BARD1 0.708 – – –
218102_at DERA 0.702 – – –
224815_at COMMD7 0.673 – – –
207877_s_at NVL 0.662 – – –
203528_at SEMA4D 0.659 – – –
205642_at CEP110 0.653 – – –
1554482_a_at SAR1B 0.652 – – –
217958_at TRAPPC4 0.644 – – –
1553984_s_at DTYMK 0.639 – – –
222894_x_at C20orf7 0.638 – – –
212491_s_at DNAJC8 0.635 – – –
Table 3. Continued
Upregulated in TTLshort Downregulated in TTLshort
Probe Set
Gene
Symbol FC Probe Set
Gene
Symbol FC
218996_at TFPT 0.627 – – –
1553957_at ZNF564 0.627 – – –
223048_at SDHAF2 0.620 – – –
217959_s_at TRAPPC4 0.620 – – –
201214_s_at PPP1R7 0.618 – – –
201452_at RHEB 0.599 – – –
209103_s_at UFD1L 0.597 – – –
204335_at CCDC94 0.589 – – –
217692_at MAGOH2 0.579 – – –
201716_at SNX1 0.570 – – –
218080_x_at FAF1 0.555 – – –
201762_s_at PSME2 0.520 – – –
221915_s_at RANBP1 0.519 – – –
Differentially regulated genes comparing TTLshort and TTLlong xenograft
expression profiles (88 probe sets, 73 genes) identified by ‘‘shrinkage
t’’ statistic, FDR < 5%. Fold change (FC) is given as logarithm (base 2),
and probe sets upregulated in TTLshort (n = 61, 51 genes) display a posi-
tive, downregulated probe sets (n = 27, 22 genes) a negative fold change
value.
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(Figure 5B).
These data on primary pediatric ALL showing an effect of both
inhibitors, predominantly on TTLshort leukemia samples, point to
a potential use as targets for directed therapy in patients at high
risk for early relapse.
DISCUSSION
We identified in vivo proliferation of de novo BCP-ALL cells
transplanted into NOD/SCID mice to be of prognostic and
predictive value for patient outcome. While slow engraftment
(TTLlong) is associated with favorable outcome, TTLshort is found
in patients with poor prognosis. This biological phenotype is
associated with a distinct cellular phenotype characterized by
a specific gene signature identifying patients with early relapse
and pointing to pathways regulating cell proliferation and
apoptosis.
Consistent with previous reports, leukemia cells engrafted in
our model of NOD/SCID/huALL retained the immunophenotypic
and clinical characteristics of the primary leukemia (Baersch
et al., 1997; Borgmann et al., 2000; Kamel-Reid et al., 1989;
Lock et al., 2002) and the proportion of leukemia cells in periph-
eral blood correlated with infiltration in different organs (Lock
et al., 2002; Nijmeijer et al., 2001). The observed engraftment
phenotype remained stable not only upon transplant of identical
cell numbers of the same leukemia sample but was also consis-
tent during consecutive passages.
Intriguingly, we found a most significant correlation of in vivo
leukemia growth and overall patient outcome (ALL-BFM
therapy). Patients whose leukemia cells showed a short time to
overt leukemia in the recipient animals (TTLshort) relapsed early
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Figure 4. mTOR as Potential Therapeutic
Target for TTLshort/Early-Relapse Leukemia
(A) TTLshort is characterized by an activated mTOR
pathway (DDIT4Llow/RHEBhigh/FRAP1high) serving
as potential target for directed therapy of
TTLshort/early-relapse leukemia.
(B) Specific cell death of xenograft ALL upon
ex vivo treatment with rapamycin (10 nM, white
columns; 100 nM, black columns) for 24, 48, or
72 hr. Time points with >90% spontaneous cell
death were not analyzed (n.a.). Data are given as
mean of triplicates with standard deviation.
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shown to be associated with poor outcome (Gaynon et al.,
1998; Henze et al., 1991). Most relapses occur in non-high risk
patients initially responding to treatment (Schrappe et al.,
2000a), indicating that these patients are not identified by the
current stratification strategies. When we focused our analysis
on this low-risk group only, we also observed a clear-cut inferior
survival of patients with TTLshort in this non-HR patient group.
A putative prognostic impact of in vivo leukemia growth on
patient outcome was investigated in a number of studies, so
far with conflicting results. This might be explained by the
small number of patients studied, the use of less permissive
recipients, or because leukemia cells from patients at relapse
were used (Kamel-Reid et al., 1991; Lock et al., 2002; Uckun
et al., 1995, 1998).
Pretreatment characteristics such as age, white blood cell
count at diagnosis, but also initial treatment response were not
significantly associated with increased relapse risk. Most impor-Cancer Cell 19, 206–217,tantly, patients with TTLshort had a 45-fold
increased relapse risk, demonstrating the
power of TTL as an independent prog-
nostic factor. TEL/AML1 fusion is associ-
ated with favorable outcome (Pui et al.,
2004a); concordantly with this, all
patients positive for TEL/AML1 (n = 19)
exhibited TTLlong in our xenotransplant
model. One patient with TTLlong included
in our study was high-risk stratified based
onMRD; all five patients with TTLshort with
available information were not detected
by MRD as high risk. Impaired reduction
of leukemia cells after treatment as
assessed by MRD is likely to be due to
resistance. Despite relapse, patients
with TTLshort are not characterized by
poor treatment response. By transplant-
ing different numbers of TTLshort and
TTLlong leukemia cells, we found that
engraftment properties are indeed
intrinsic to the leukemia cell itself and
are retained independently of the cell
number transplanted. Also, NOD/SCID/
huALL established from cryopreserved
leukemia cells in the test set showed an
identical correlation of TTL and time torelapse as NOD/SCID/huALL established from fresh samples in
our study. These results are in line with observations showing
the engraftment ability to be an inherent property also of AML
cells transplanted (Monaco et al., 2004; Pearce et al., 2006).
We identified a specific TTL-gene profile with robust clustering
and inferior relapse-free survival of the TTLshort signature group if
applied onto an independent patient cohort. Signatures associ-
ated with treatment response and relapse in pediatric ALL
have been previously reported (Bhojwani et al., 2006; Cario
et al., 2005; Flotho et al., 2007; Holleman et al., 2004; Lugthart
et al., 2005; Yeoh et al., 2002); however, based on the TTL profile,
a classifier was also obtained, robustly identifying this very high-
risk group of patients with early relapse.
Importantly, these findings also point to activated pathways
associated with poor outcome indicating additional therapeutic
targets. mTOR is a central downstream switch integrating
diverse pathways involved in cell growth and survival (Brown
et al., 1994). DDIT4L negatively regulates the mTOR pathwayFebruary 15, 2011 ª2011 Elsevier Inc. 213
apoptosis
PDE4A
high
cAMP cAMP 
PD-esterase- inhibitors
(e.g. rolipram)
apoptosis
B
A
ro
lip
ra
m
: s
pe
ci
fic
 c
el
l d
ea
th
 [%
] 
TTLshort LTT long
100%
50%
0%
100%
50%
0%
100%
50%
0%
100%
50%
0%
24h 48h 72h 24h 48h 72h 
24h 48h 72h 24h 48h 72h 
24h 48h 72h 24h 48h 72h 
24h 48h 72h 
100%
50%
0%
100%
50%
0%
100%
50%
0%
24h 48h 72h 24h 48h 72h 
24h 48h 72h 24h 48h 72h 
24h 48h 72h 24h 48h 72h 
X002
X018 X089
X120 X131
X132
X006 X032 X043
X068 X076
X112 
X121
10µM
100µM
n.a. n.a. 
n.a.
24h 48h 72h 
X116 
100%
50%
0%
Figure 5. Inhibition of PDE4A Induces Cell
Death Predominantly in TTLshort/Early-
Relapse Leukemia
(A) Predominant effect of phosphodiesterase
inhibitors on TTLshort/early-relapse leukemia asso-
ciated with high PDE4A.
(B) Specific cell death of xenograft leukemia
samples ex vivo incubated with rolipram (10 mM,
white columns; 100 mM, black columns) for 24,
48, or 72 hr. Time points with >90% spontaneous
cell death were not analyzed (n.a.). Data are given
as mean of triplicates with standard deviation.
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2005) and is highly expressed in TTLlong, suggesting a more effi-
cient control of mTOR in this subgroup. Vice versa, leukemias
showing downregulated DDIT4L might lack repression of
mTOR, thereby exhibiting TTLshort and impaired outcome.
Most interestingly, RHEB, directly binding to the mTOR
complex and thereby enabling mTOR activation (Long et al.,
2005), was identified in the TTL signature by two probe sets.
RHEB is upregulated in TTLshort, accounting for increased acti-
vation of the mTOR pathway. Furthermore, upregulation of
FRAP1 (mTOR) itself was also strongly associated with TTLshort,
underlining the relevance of this pathway positively regulating
cell proliferation for early-relapse leukemia.
Taken together, the TTLshort phenotype is characterized by
DDIT4Llow/RHEBhigh/FRAP1high, indicating an activated mTOR
pathway in the TTLshort/early-relapse leukemias. These results
have important therapeutic implications because the activated
mTOR pathway can be directly targeted inhibiting growth of
TTLshort leukemia. Rapamycin and related mTOR inhibitors214 Cancer Cell 19, 206–217, February 15, 2011 ª2011 Elsevier Inc.have been shown to inhibit leukemia
growth and induce apoptosis in BCP-
ALL in vitro and in vivo alone or in
combination with established chemo-
therapeutic drugs (Brown et al., 2003;
Crazzolara et al., 2009; Teachey et al.,
2006, 2008), and similarities of drug-
associated signatures identified rapamy-
cin to induce glucocorticoid sensitivity in
ALL cells (Wei et al., 2006). In fact,
TTLshort leukemias were more sensitive
to ex vivo rapamycin treatment than
TTLlong samples. The individual xenograft
leukemias showed heterogeneous sensi-
tivities suggesting additional mecha-
nisms responsible for the TTL phenotype.
Indeed, additional genes involved in cell
proliferation and apoptosis were identi-
fied in the TTL signature.
PDE4A downregulates cAMP levels,
leading to impaired apoptosis sensitivity
(Jiang et al., 1996), and was, in line with
this function, found to be upregulated in
TTLshort leukemia. Inhibition of PDE4A
activity using compounds like rolipram
resulted in increased glucocorticoidsensitivity and apoptosis in leukemia cells (Meyers et al., 2007;
Moon and Lerner, 2003; Ogawa et al., 2002). Treatment of xeno-
graft leukemia samples with rolipram in fact induced cell death
predominantly in TTLshort leukemia cells.
DAPK1, a tumor suppressor gene whose expression is lost by
epigenetic silencing in a number of different tumors, including
hematopoietic malignancies (Esteller et al., 1999; Katzenellenb-
ogen et al., 1999; Kissil et al., 1997; Raval et al., 2007; Sanchez-
Cespedes et al., 2000), codes for a serine/threonine kinase that
positively regulates apoptosis and suppresses tumor progres-
sion in vivo (Cohen et al., 1999; Deiss et al., 1995; Inbal et al.,
1997). Consistent with these reports, DAPK1 was identified to
be downregulated in TTLshort, suggesting that TTLshort cells
evade from cell death by loss of this proapoptotic regulator.
Along this line, we previously reported that deficient apoptosis
signaling via the intrinsic pathway is a feature of poor prognosis
in primary pediatric ALL and AML (Meyer et al., 2006, 2008). In
contrast to its proapoptotic and tumor-suppressing function, up-
regulated DAPK1 expression was reported in pediatric ALL
Cancer Cell
NOD/SCID/huALL Engraftment Identifies ALL Relapsesamples resistant to in vitro prednisolone treatment (Holleman
et al., 2006). However, TTL is independent of glucocorticoid
resistance, with five of six patients with TTLshort being predni-
sone-good responders, indicating that the engraftment pheno-
type of primary ALL cells reflects constitutional hallmarks of
the leukemia.
Taken together, the proliferative capacity of primary ALL cells
in NOD/SCID mice appears to reflect intrinsic properties of the
leukemia cells and determines relapse in pediatric ALL. TTLshort
is characteristic for patients with early relapse and associated
with a specific gene profile. The biological impact of our obser-
vations in the xenotransplant model could be demonstrated in
an independent group of patients and led to identification of
distinct pathways involved in regulation of cell growth and
apoptosis that can be targeted by well-known drugs such as
rapamycin. Thus, our NOD/SCID/huALL model provides
a powerful tool to identify prognostic factors in acute leukemia
at a cellular and molecular level, leading to rational targets for
therapeutic intervention strategies.
EXPERIMENTAL PROCEDURES
Detailed information with respect to methods andmaterials used is available in
the Supplemental Experimental Procedures.
Patients and Leukemia Samples
Leukemia samples were obtained at diagnosis from pediatric patients with de
novo BCP-ALL after informed consent was given in accordance with the insti-
tution’s ethical review board (Ethikkommission Universita¨t Ulm). Patients were
enrolled into the ALL-BFM (Schrappe et al., 2000a) or the AIEOP LLA 2000
study protocol (Conter et al., 2000); both studies are performed in accordance
to the Declaration of Helsinki and are registered at http://clinicaltrials.gov
(ALL BFM 2000: NCT00430118; and AIEOP LLA 2000: NCT00613457).
NOD/SCID/huALL and TTL
All experimental animal studies were conducted according to the national
animal welfare law (Tierschutzgesetz) and were approved by the appropriate
authority (Regierungspra¨sidium Tu¨bingen, Germany, experiment number
775). Patient samples were isolated from diagnostic specimens and consisted
of more than 90% leukemia cells. Unconditioned NOD/LtSz-scid/scid mice
were transplanted by intravenous injection of 1 3 107 cells per recipient
throughout the study. As an exception, different numbers were injected if
the impact of the cell dose was analyzed. TTL was determined for each patient
sample transplanted as weeks from transplant to clinical leukemia manifesta-
tion. ALL cells were detected, and leukemia was confirmed in peripheral blood,
bone marrow, or spleen by flow cytometry (Lock,et al., 2002). Mice without
evidence for disease at week 20 after transplant were killed, and absent
leukemia infiltration of spleen or bone marrow confirmed no leukemia.
Gene Expression and Statistical Analysis
Gene expression analysis was carried out on xenograft leukemia samples with
sufficient follow-up time and negative for known cytogenetic abnormalities
(n = 12: TTLshort n = 5 and TTLlong n = 7) isolated from recipients with overt
leukemia. Expression profiles of the validation cohort (n = 197) were obtained
from diagnostic specimens from patients treated according to the AIEOP LLA
2000 protocol. Expression was analyzed using the Human Genome U133 Plus
2.0 Array platform. Gene expression microarray files (Affymetrix .CEL files)
were generated using the GCOS 1.4 or 1.2 software (Affymetrix). Arrays
have been normalized using robust multiple-array average (RMA) (Gautier
et al., 2004). Expression data were analyzed using Bioconductor package
for R (v2.11.1). Differentially expressed genes have been calculated by the
shrinkage T-statistic (Opgen-Rhein and Strimmer, 2007). Multiple comparison
results were controlled by maintaining a FDR < 0.05 (Strimmer, 2008). The
signature of 88 differentially expressed probe sets was applied to profiles of
197 independent patients with BCP-ALL. A robust clustering method basedCon the K-means algorithm has been applied to estimate the correct number
of clusters in this data set (Kraus and Kestler, 2010). Kaplan-Meier analysis
has been performed of relapse-free survival in the two clusters obtained
from the cluster analysis. Classification into TTLshort and TTLlong classes was
computed with a SCM algorithm (Kestler et al., 2006; Marchand and Shawe-
Taylor, 2002), and a leave-one-out method has been used to validate the
classifier.
All other statistical analyses were carried out using SPSS 11.0 software
(SPSS, Munich, Germany) or ‘‘R’’ (v. 2.11.1) (R-Development-Core-Team,
2010); p values of <0.05 were considered significant in all tests carried out in
this study.
Ex Vivo Treatment of Xenograft Leukemia
Leukemia cells were isolated from recipient animals as described and incu-
bated with either rapamycin (10 and 100 nM) or rolipram (10 and 100 mM)
diluted in dimethyl sulphoxide (DMSO) or DMSO alone, and cell viability was
assessed by flow cytometry (forward/side scatter criteria).
ACCESSION NUMBERS
Data have been deposited in NCBI’s Gene Expression Omnibus (GEO) data-
base (http://www.ncbi.nlm.nih.gov/geo) and are accessible through GEO
Series accession number GSE13576.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and eight tables and can be found with this article online at
doi:10.1016/j.ccr.2010.11.014.
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